Elke Butterbrod

Dr. Elke Butterbrod

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2019 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
EBElke Butterbrod
Elke Butterbrod
JBJimme Bruijn
Jimme Bruijn
MBMeriam M. Braaksma
Meriam M. Braaksma
GRGeert-Jan M. Rutten
Geert-Jan M. Rutten
CTCees C. Tijssen
Cees C. Tijssen
KGKarin Gehring
Karin Gehring
Purpose: Progressive disease in patients with high-grade glioma may be reflected in cognitive decline. However, the cognitive functions most sensitive to progression may differ between patients. We investigated whether decline on a personalized selection of tests predicted progressive disease according to RANO criteria in high-grade glioma patients. Methods: Starting one day before surgery, patients underwent neuropsychological assessment every three months during standard treatment and clinical follow-up. We first made a personalized selection of three tests that showed the highest Reliable Change Index (RCI) values, i.e., most positive change, at the first post-surgical assessment for each patient. In subsequent follow up, a decline of RCI ≤ − 1 on at least two of the three tests in the selection was considered cognitive decline. We performed a discrete Cox proportional hazards model including a time-dependent coefficient cognitive decline (vs. stability) and covariate age to predict progressive disease. Results: Twenty five patients were included. Cognitive decline on the personalized test selection preceded or had occurred by the time progression was established in 9/15 patients with RANO confirmed progressive disease (60%). Decline was absent in 8/10 patients (80%) with stable disease during participation. The independent hazard ratio for progression in case of cognitive decline was 5.05 (p < 0.01) compared to stable performance. Conclusions: Using only three patient-specific neuropsychological tests, we found a fivefold increased chance of disease progression in case of cognitive decline as compared to stable performance. Brief, patient-tailored cognitive assessment may be a noninvasive addition to disease monitoring without overburdening patients and clinical care.

8 July 2020 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
EBElke Butterbrod
Elke Butterbrod
NSNathalie Synhaeve
Nathalie Synhaeve
GRGeert-Jan Rutten
Geert-Jan Rutten
ISInga Schwabe
Inga Schwabe
KGKarin Gehring
Karin Gehring
MSMargriet Sitskoorn
Margriet Sitskoorn
Purpose: Cognitive functioning is increasingly investigated for its prognostic value in glioblastoma (GBM) patients, but the association of cognitive status during early adjuvant treatment with survival time is unclear. The aim of this study was to determine whether cognitive performance three months after surgical resection predicted survival time, while using a clinically intuitive time ratio (TR) statistic.Methods: Newly diagnosed patients with GBM undergoing resection between November 2010 and February 2018 completed computerized cognitive assessment 3 months after surgery with the CNS Vital Signs battery (8 measures). The association of cognitive performance (continuous Z scores and dichotomous impairment status; impaired vs. unimpaired) with survival time was assessed with multivariate Accelerated Failure Time (AFT) models that also included clinical prognostic factors and covariates related to cognitive performances.Results: 114 patients were included in the analyses (median survival time 16.4 months). Of the clinical factors, postoperative Karnofsky Performance Status (TR 1.51), surgical (TR 2.20) and non-surgical (TR 1.94) salvage treatment, and pre-surgical tumor volume (cm3, TR 1.003) were significant independent predictors of survival time. Independently of the base model factors and covariates, impairment on Stroop test I and Stroop test III estimated 23% and 26% reduction of survival time (TR 0.77, TR 0.74) respectively, as compared to unimpaired performance.Conclusion: These findings suggest that impaired performances on tests of executive control and processing speed in the early phase of adjuvant treatment can reflect a worse prognostic outlook rather than an early treatment effect, and their assessment might allow for early refinement of current prognostic stratification.

1 September 2020 in Journal of Neurosurgery
Verified
Journal Article
Closed access
PDF file
EBElke Butterbrod
Elke Butterbrod
KGKarin Gehring
Karin Gehring
EVEduard H. Voormolen
Eduard H. Voormolen
PDPaul R. A. M. Depauw
Paul R. A. M. Depauw
WNWilly-Anne Nieuwlaat
Willy-Anne Nieuwlaat
MSMargriet M. Sitskoorn
Margriet M. Sitskoorn
OBJECTIVE: Patients with nonfunctioning pituitary adenomas (NFPAs) can suffer from cognitive dysfunction. However, the literature on longitudinal cognitive follow-up of patients undergoing endoscopic endonasal transsphenoidal surgery (EETS) is limited. This study was performed to investigate perioperative cognitive status and course in patients with NFPAs.METHODS: Patients underwent computerized neuropsychological assessment 1 day before (n = 45) and 3 months after (n = 36) EETS. Performance in 7 domains was measured with a computerized test battery (CNS Vital Signs) and standardized using data from a healthy control group. The authors conducted analyses of cognitive performance at both time points and changes pre- to post-ETSS on a group and an individual level. Linear multiple regression analyses were employed to investigate predictors of cognitive performance.RESULTS: On average, patients scored significantly lower in 6 of 7 cognitive domains before and after surgery than controls. Impairment proportions were significantly higher among patients (56% before surgery, 63% after surgery) than among controls. Patients showed no change over time in group-level (mean) performance, but 28% of individual patients exhibited cognitive improvement and 28% exhibited cognitive decline after surgery. Hormonal deficiency showed a positive correlation with verbal memory before surgery. Postoperative performances in all cognitive domains were predicted by preoperative performances.CONCLUSIONS: Cognitive impairment was present before and after EETS in over half of NFPA patients. Individual patients showed diverse postoperative cognitive courses. Monitoring of cognitive functioning in clinical trajectories and further identification of disease-related and psychological predictors of cognition are warranted.

20 December 2020 in European Journal of Neurology
Verified
Journal Article
Open access
PDF file
EBElke Butterbrod
Elke Butterbrod
MSMargriet Sitskoorn
Margriet Sitskoorn
MBMarjan Bakker
Marjan Bakker
BJBernadette Jakobs
Bernadette Jakobs
RFRuth Fleischeuer
Ruth Fleischeuer
KGKarin Gehring
Karin Gehring
Background: Recent studies suggest a relationship between the APOE ε4 allele and cognitive outcome in patients treated for malignant brain tumors. Still, longitudinal investigations that include a pretreatment cognitive assessment are lacking and APOE’s effects in patients with benign tumors are understudied. This study investigated presurgical cognitive performance and postsurgical change in ε4‐carrying and non‐carrying patients with glioma and meningioma.Methods: Neuropsychological test scores (CNS Vital Signs battery [seven measures], Digit Span Forward/Backward, Letter Fluency test) were obtained as part of a prospective study in which patients with meningioma and glioma underwent cognitive assessment 1 day before (T0,n = 505) and 3 (T3,n = 418) and 12 months after (T12,n = 167) surgery. APOE isoforms were identified retrospectively. ε4 carriers and non‐carriers were compared with regard to pretreatment cognitive performance on the group and individual level. Changes in performances over time were compared with longitudinal mixed model analysis in the total sample and the subgroup receiving adjuvant treatment.Results: Carriers and non‐carriers did not differ with regard to pretreatment performance. No significant main effect of ε4 carrier status or interaction between time (T0–T12) and carrier status was found on any of the tests in the whole sample nor in the sample receiving adjuvant treatment.Conclusions: This study found no evidence of increased vulnerability for pretreatment cognitive dysfunction or cognitive decline within 1 year after surgery in APOE ε4‐carrying meningioma and glioma patients. Investigations that include larger samples at longer‐term follow‐up are recommended to investigate potential late treatment effects.

21 October 2024 in Journal of the International Neuropsychological Society
Verified
Journal Article
Open access
PDF file
EBElke Butterbrod
Elke Butterbrod
DHDominique M.J. van Den Heuvel
Dominique M.J. van Den Heuvel
PZPia Zevenhoven
Pia Zevenhoven
LWLisa Waterink
Lisa Waterink
MLMardou van Leeuwenstijn
Mardou van Leeuwenstijn
SSSietske A.M. Sikkes
Sietske A.M. Sikkes
Objective: Neuropsychological assessment through VideoTeleConferencing (VTC) can help improve access to diagnostic and follow-up care in memory clinics. This study investigated the stability of performance on VTC assessment in relation to in-person assessment using a test-retest design and explored user experiences of VTC assessment.Materials and Methods: Thirty-one patients (62 ± 6.7 years, 45% female, 58% Subjective Cognitive Decline, 42% Mild Cognitive Impairment/dementia diagnosis) were included from the Amsterdam Dementia Cohort between August 2020 and February 2021. Patients underwent a face-to-face neuropsychological assessment followed by a VTC assessment using the same test protocol within 4 months. Reliability coefficients were calculated using intraclass correlation coefficients (ICC). For each test, the proportion of clinically relevant differences in performances between assessment modalities was calculated. User experiences of patients and neuropsychologists were assessed with questionnaires (User Satisfaction and Ease of use [USE] questionnaire and System Usability Scale [SUS]). Neuropsychologists also participated in a focus group.Results: ICC values were moderate to excellent (0.63-0.93) for all test measures in the total sample. On all tests, most patients did not show clinically relevant performance differences between modalities. Patients and neuropsychologists reported overall positive VTC system usability, although neuropsychologists indicated in the focus group that patients without cognitive impairment required less training for the system and were more independent.Conclusion: VTC assessment showed adequate to excellent test-retest reliability for a broad range of neuropsychological tests commonly used in practice. Assessment through VTC may be a user friendly method in the memory clinic, especially to monitor individuals at risk for future cognitive decline.

1 December 2024 in Alzheimer's & Dementia
Verified
Journal Article
Open access
RBRosanne L. van Den Berg
Rosanne L. van Den Berg
EBElke Butterbrod
Elke Butterbrod
CBCasper de Boer
Casper de Boer
DSDemi van de Scheur
Demi van de Scheur
LSLisa‐Marie Schlüter
Lisa‐Marie Schlüter
SSSietske A.M Sikkes
Sietske A.M Sikkes
Background: Verbal fluency, especially semantic fluency, may hold promise to predict clinical progression in the preclinical Alzheimer’s disease (AD) stage, where patients show no objective cognitive impairment. We examined verbal fluency trajectories in amyloid‐negative and amyloid‐positive individuals with subjective cognitive decline (SCD), as well as whether baseline fluency characteristics (total scores and item‐level) predicted progression to MCI or AD dementia.Method: We retrospectively selected data of 471 Dutch individuals with SCD, with at least 1 follow‐up fluency assessment, from the Amsterdam Dementia Cohort (Follow‐up years = 4.3±2.9, Age = 61±8, Female n = 199(42%), Amyloid‐positive n = 131(28%), clinical progression n = 66(14%), Table 1). We longitudinally measured total scores for semantic (animals) and phonemic fluency (alternate versions) and semantic‐phonemic‐discrepancy scores (subtracting phonemic from semantic fluency). For a subset (n = 82) we obtained baseline item‐level characteristics: lexical frequency and word length (both continuous), errors, repetitions and duplications between semantic and phonemic fluency (all dichotomized). We compared baseline fluency measures between amyloid groups and clinical progression groups. Fluency trajectories and their associations with amyloid‐status were examined with linear mixed models. We examined associations between baseline fluency and progression to MCI/AD dementia using Cox proportional hazard models. Cox models for total and discrepancy scores were performed in the total group including a fluency*amyloid interaction, whereas models for item‐level metrics only included amyloid‐positive individuals (n = 44). All models were adjusted for age, sex and education.Results: At baseline no significant differences in any of the fluency measures between amyloid groups were observed (p’s > 0.05, Table 2). Longitudinally, amyloid‐positive individuals declined more steeply on semantic fluency (β = ‐0.37,95%CI = ‐0.53—0.20) and phonemic‐semantic‐discrepancy (β = ‐0.32,95%CI = ‐0.49—0.14) compared to amyloid‐negative individuals. Groups did not differ on phonemic fluency (β = ‐0.05,95%CI = ‐0.15–0.05, Figure 1). While baseline discrepancy scores were lower in patients who later progressed (Mean = 9.0±SD = 5.4) than in non‐progressors (Mean = 10.7±SD = 5.1,W = 14317,p = 0.023), none of the baseline fluency measures predicted clinical progression after adjusting for covariates (p’s>0.05).Conclusion: Longitudinal decline in semantic fluency and discrepancy scores, but not phonemic fluency, was associated with amyloid positivity in individuals with SCD. Baseline fluency did not predict clinical progression. These findings suggest that longitudinal follow‐up is essential to capture semantic fluency decline that is associated with AD pathophysiology.